KESIMPTA (ofatumumab)

**Product type:** Human Prescription Drug

**Active ingredient:** OFATUMUMAB

**Strength:** 20 mg/.4mL

**Dosage form:** Injection, Solution

**Route:** Subcutaneous

**Labeler:** Novartis Pharmaceuticals Corporation

**Marketing category:** BLA (BLA125326)

**Pharmacologic class:** CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]